Radnostix, Inc. Reports FY2026 Q1 Results - Revenue Declines 27% Primarily Due to Voluntary Product Recalls, Isotope Supply Disruptions, and Planned Operational Shutdown

Radnostix’s turnaround story is all talk—numbers show deepening losses and shrinking cash.

What the company is saying

Radnostix, Inc. (OTCQB:INIS) wants investors to believe it is on the cusp of a major operational and financial rebound, despite a disastrous quarter. The company’s core narrative is that recent setbacks—recalls, isotope shortages, and Cobalt-60 downtime—are temporary, and that new investments in facilities and product lines will soon drive growth. Management frames these claims with phrases like 'positioning the Company for significant capacity expansion and product portfolio growth in 2026' and 'strengthen our manufacturing resilience,' emphasizing future potential over current performance. The announcement spotlights the completion of a new Calibration & Reference Products facility, the repair of the Cobalt-60 hot cell, and the mutual termination of a DUF6 asset sale agreement as strategic wins. However, it buries the fact that revenue and gross profit have collapsed, and that net losses have ballooned more than tenfold year-over-year. The tone is defensive but tries to project confidence, using aspirational language and forward-looking statements to distract from the negative financials. Shahe Bagerdjian, President and CEO, is the only notable individual mentioned, and his involvement is standard for a company of this size—there is no evidence of outside institutional backing or high-profile investors. This narrative fits a classic playbook: acknowledge short-term pain, promise near-term recovery, and highlight long-dated opportunities, all while providing little hard evidence of execution. Compared to prior communications (which are not available for review), there is no sign of a shift in messaging, but the heavy reliance on future promises over present results is notable.

What the data suggests

The disclosed numbers paint a starkly negative picture. Total revenue for Q1 2026 fell 27% to $2,378,924 from $3,238,900 in Q1 2025, confirming a sharp contraction in the company’s top line. Gross profit dropped even more steeply, down 43% to $1,150,948, indicating that cost pressures or unfavorable sales mix compounded the revenue decline. Net loss exploded to $1,348,086 from just $112,694 a year earlier, a more than tenfold increase, showing that operational disruptions and higher expenses have severely eroded profitability. Cash and cash equivalents fell to $1,350,000 from $1,700,000 at year-end, and net cash used in operating activities was $72,442, suggesting ongoing cash burn with no offsetting inflows. Operating expenses rose 7% to $2,460,980, despite the revenue collapse, further squeezing margins. EBITDA swung from a positive $47,278 to negative $950,144, and adjusted EBITDA from $117,557 to negative $923,310, both clear signs of deteriorating core performance. The company provides no segment breakdowns, product-level sales, or operational KPIs, making it impossible to verify claims about facility utilization or product launches. An independent analyst would conclude that the company is in a worsening financial position, with no evidence in the numbers to support management’s optimism about a near-term turnaround.

Analysis

The announcement's tone attempts to offset significant negative financial results with forward-looking statements about facility expansion, product launches, and operational recovery. While the company discloses a 27% revenue decline and a much larger net loss, it emphasizes the completion of new facilities and asset repairs as positioning for future growth. However, most of the positive claims are forward-looking and lack supporting quantitative evidence or binding agreements. The capital outlays for new facilities and repairs are disclosed, but the benefits are projected for 2026 and beyond, with no immediate earnings impact. The narrative inflates the signal by focusing on potential future capacity and resilience rather than addressing the current operational and financial deterioration. The data supports only the negative financial trends, not the anticipated turnaround.

Risk flags

• ●Operational risk is acute: the company suffered a 27% revenue drop and a 43% gross profit decline in a single quarter, driven by recalls, isotope shortages, and Cobalt-60 downtime. This demonstrates vulnerability to supply chain and quality control disruptions, which could recur.
• ●Financial risk is high: net loss ballooned from $112,694 to $1,348,086 year-over-year, and cash reserves fell to $1.35 million. With ongoing cash burn and no evidence of new financing, there is a real risk of liquidity crunch if performance does not improve quickly.
• ●Disclosure risk is significant: while headline financials are provided, there is no segment or product-level detail, no customer concentration data, and no operational KPIs. This lack of transparency makes it difficult for investors to assess the true drivers of performance or the likelihood of recovery.
• ●Execution risk is elevated: most positive claims are forward-looking, with benefits projected for late 2026 or later. The company has not demonstrated an ability to deliver on similar initiatives in the past, and there are no disclosed milestones or binding agreements to track progress.
• ●Capital intensity risk is present: the company has invested in new facilities and asset repairs, but the payoff is distant and uncertain. If projected growth does not materialize, these sunk costs could further strain the balance sheet.
• ●Pattern risk: the announcement follows a familiar pattern of using aspirational language and future promises to offset poor current results. This is often a red flag for companies struggling to execute.
• ●Timeline risk: with most benefits at least two quarters away and no immediate catalysts, investors face prolonged uncertainty. If operational recovery is delayed, further financial deterioration is likely.
• ●Leadership risk: while the CEO is named, there is no evidence of outside institutional support or new strategic investors. The absence of third-party validation increases the risk that management’s optimism is not grounded in external reality.

Bottom line

For investors, this announcement signals a company in distress, not one on the verge of a turnaround. The numbers show a business with shrinking revenue, collapsing margins, and accelerating losses, while cash reserves dwindle. Management’s narrative is almost entirely forward-looking, with promises of operational recovery and new product launches that are at least two quarters away from being testable. There is no evidence of new customer contracts, binding agreements, or immediate revenue impact from recent investments. The absence of detailed disclosures on segment performance or operational KPIs further undermines credibility. If a notable institutional figure had participated, it might signal external validation, but in this case, only the CEO is named, and his involvement is expected. To change this assessment, the company would need to provide hard evidence of restored production, signed sales agreements, or immediate financial improvement. Key metrics to watch in the next quarter are revenue rebound, gross margin recovery, cash burn rate, and any concrete progress on facility utilization or product launches. At present, this is a weak negative signal: investors should monitor for signs of real operational recovery, but there is no basis for action until the numbers turn. The single most important takeaway is that Radnostix’s story is all about future potential, but the current financials show a company in deep trouble.

Announcement summary

Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB:INIS), a manufacturer of radioisotope-focused products, announced its financial results for the first quarter ended March 31, 2026. Total revenue decreased 27% to $2.38 million from $3.24 million in the first quarter of 2025, primarily due to recall impacts, isotope shortages, and Cobalt-60 down time. Gross profit dropped 43% to $1.15 million, and the company reported a net loss of $1,348,086 compared to a net loss of $112,694 in the prior-year period. Cash and cash equivalents at quarter-end were $1.35 million, down from $1.70 million at December 31, 2025. Operational highlights include the completion of a new Calibration & Reference Products manufacturing facility, repair and retrofit of the Cobalt-60 hot cell, and the mutual termination of the DUF6 asset sale agreement. The company is preparing for new product launches and further facility expansion in 2026. Radnostix anticipates that the negative impacts from recalls and maintenance will not extend beyond Q2 and is focused on restoring operations and expanding its product portfolio.

Disagree with this article?